Categories
Change Password!
Reset Password!
Patients with refractory
migraine can use anti-CGRP
monoclonal antibodies for headache and migraine pain relief.
A recent real-world clinical practice study
published in the Journal of Neurology concluded the use of monoclonal
antibodies against calcitonin gene-related
peptide (CGRP) therapy to be effective in patients with refractory
migraine.
To examine the frequency and
headache-related impact response to monoclonal antibodies against CGRP, a total
of 155 patients with monthly ≥ 8 headache days (with unsuccessful response to a
minimum of 3 preventive medicines like erenumab and
galcanezumab) were considered. These
patients were asked to fill an
electronic headache diary comprising of number of headache
and
migraine days in a month, headache pain
intensity (numerical
scale) and analgesics usage. The Patient-Reported Outcome
questionnaires at starting
of therapy
and following
12 weeks were also completed. On the basis of improvement in the frequency of
headache and migraine, the patients were categorized
into ≥ 50%,
≥ 75% and 100% responders.
A reduction in headache frequency as - 9.1 headache days per month and - 8.5 migraine days per month was observed after 12 weeks of the treatment. The number of patients who described ≥ 50%, ≥ 75% and 100% headache and migraine days per month decrease has been portrayed in the following table:
Distinct improvements were witnessed for all
patient-reported outcomes in the ≥ 50% migraine days/month-responders group.
Less severe disability was noted in patients who were not on other preventive
medicines and a higher percentage of monthly migraine over headache days were
more probably associated with ≥ 50% migraine days per month-responder.
Constipation (20%), fatigue (7.1%) and a temporary rise in blood pressure
(5.2%) were most frequently recorded adverse events.
Journal of Neurology
The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study
Marta Torres-Ferrús et al.
Comments (0)